These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 16220296

  • 1. Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool.
    Rudzki Z, Kawa R, Okoñ K, Szczygieł E, Stachura J.
    Virchows Arch; 2006 Jan; 448(1):59-67. PubMed ID: 16220296
    [Abstract] [Full Text] [Related]

  • 2. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 3. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [Abstract] [Full Text] [Related]

  • 4. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J.
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [Abstract] [Full Text] [Related]

  • 5. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K, Bock O, Kreipe H.
    Pathobiology; 2007 Feb; 74(2):72-80. PubMed ID: 17587878
    [Abstract] [Full Text] [Related]

  • 6. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ, Thiele J.
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [Abstract] [Full Text] [Related]

  • 7. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.
    Gianelli U, Vener C, Raviele PR, Moro A, Savi F, Annaloro C, Somalvico F, Radaelli F, Franco V, Deliliers GL.
    Leuk Lymphoma; 2006 Sep; 47(9):1774-81. PubMed ID: 17064987
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
    Michiels JJ.
    Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
    [Abstract] [Full Text] [Related]

  • 9. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 10. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
    Michiels JJ, Juvonen E.
    Semin Thromb Hemost; 1997 Sep; 23(4):339-47. PubMed ID: 9263350
    [Abstract] [Full Text] [Related]

  • 11. Quantitative cytomorphology of megakaryocytes in chronic myeloproliferative disorders--analysis of planimetric and numeric characteristics by means of a knowledge based system.
    Nafe R, Kaloutsi V, Fritsch RS, Georgii A.
    Exp Pathol; 1990 Sep; 40(4):213-9. PubMed ID: 2098268
    [Abstract] [Full Text] [Related]

  • 12. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
    Campr V.
    Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
    [Abstract] [Full Text] [Related]

  • 13. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O, Loch G, Schade U, von Wasielewski R, Schlué J, Kreipe H.
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [Abstract] [Full Text] [Related]

  • 14. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ.
    Hematol J; 2004 Apr; 5(2):93-102. PubMed ID: 15048058
    [Abstract] [Full Text] [Related]

  • 15. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
    Kreft A, Büche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ.
    Acta Haematol; 2005 Apr; 113(2):137-43. PubMed ID: 15802893
    [Abstract] [Full Text] [Related]

  • 16. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [Abstract] [Full Text] [Related]

  • 17. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Jun; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J.
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.